Report 2016

Scientific Working Group
“Bleeding & Thrombosis”

Chair: Anna Falanga - Hospital Papa Giovanni XXIII, Bergamo, Italy

Members: Federici AB (University of Milan, Italy), Leebeek F (University of Rotterdam), Levi M (University of Amsterdam), Kytle P (University of Vienna), Toh CH (Royal Liverpool and Broadgreen University Hospitals), Nowak-Gottl U (Department of Pediatrics, University Hospital Münster, Germany), Vicente VG (Univ. of Murcia, Spain), Gerotziasf G (Université Paris VI, Hôpital Universitaire Tenon, Paris), Kappelmayer J (Department of Laboratory Medicine, Univ. Debrecen, Hungary), ten Cate H (University of Maastricht, NL), Bauersachs RM (Medical Department IV, Max Ratschow Clinic, Darmstadt, Germany), Kakkar AK (University College London), Agnelli G (University of Perugia, Italy), Pabinger I (University of Vienna), Di Nisio M (University of Chieti, Italy), Marchetti M (Hospital Papa Giovanni XXIII, Bergamo, Italy), Castoldi E (University of Maastricht, NL), Castaman G (University of Florence, Italy), Makris M (London, UK)

The objectives of the SWG on ‘Bleeding and Thrombosis’ include: 1) To promote education in the field of bleeding and thrombosis among hematologists; 2) To favor networking and collaborations among scientists in Europe working on basic, clinical, and social aspects of bleeding and thrombotic disorders; and 3) To increase the awareness of patients and physicians about thrombotic and hemorrhagic diseases.

Activities 2016


More than 550 participants from 38 different Countries attended the ICHTIC 2016, with a very high and interactive participation to all sessions. At the start of the EHA-SWG session, Anna Falanga could present the role and activities of SWGs in the EHA organization and could announce the coming meeting of the EHA-SWG on Bleeding and Thrombosis, planned for September 2016 in Barcelona. A flyer to advertise this EHA event was included in all congress bags; flyers were also distributed in the exhibitors’ area. Overall, it was a very good opportunity to publicize the EHA work in general. A supplement of the journal ‘Thrombosis Research’ was published containing all lectures and abstracts of the Conference, including those presented at the EHA-SWG-dedicated session. This has become an additional tool to disseminate the material presented at the conference and hopefully will continue to push the interest of physicians and researchers towards the field of coagulation.

An Education Session of the SWG on Bleeding &Thrombosis was organized during the 21th EHA Congress, in Copenhagen, June 2016. The Session was entitled ‘Hot topics in risk assessment and treatment of venous thrombosis’, with three talks: 1) Genomics and NGS in thrombosis (speaker: P Reitsma, Univ. of Leiden, NL); 2) When and how to test for heparin-induced thrombocytopenia (HIT) antibodies? (speaker: Y Gruel Gresele, Univ. François Rabelais, Tours, FR); 3) Antidotes for novel oral anticoagulants (speaker: JM Connors, Harvard Univ., Boston, USA). This session was very well attended with active participation and discussion.
Much efforts of this SWG in 2016 were devoted to the organization of the second joint symposium in conjunction with the SWG on Thrombocytopenias and Platelet Function Disorders, entitle “Bleeding Disorders: Increase your knowledge and improve patient care!” (Chairs: C. Balduini, A. Falanga, I. Pabinger, F. Rodeghiero, M. Makris)). This symposium was proposed and approved by the EHA education Committee in 2015. This time it was focused particularly on bleeding disorders. It took place on September 14-16, 2016, in Barcelona, Spain. The meeting was successful with about 150 participants. In addition to the plenary sessions, it included parallel sessions, interactive sessions, one session on patient organizations and industry, and poster walk sessions.

The EHA Education Committee approved the proposal of the SWG on Bleeding and Thrombosis to have a Session at the 22nd EHA Congress in Madrid in June 2017.

Other activities:
All the members of this SWG or their collaborators presented data at ASH 2016 or to other meetings (National and International congresses relevant to the field of Hemostasis and Thrombosis) and are very actively publishing in this field.

A. Falanga sits on the board of councilors of the International Society of Thrombosis and Haemostasis (ISTH). In 2016 she acted as a chair (for EHA) of the committee for evaluating and granting the EHA-ISTH fellowship. She also represents ISTH on the board of EBAH.

Selected publications 2016:

Italian intersociety consensus on DOAC use in internal medicine.

XXIV National Congress of the Italian Society for Thrombosis and Hemostasis - SISET: Abano Terme (PD), Italy 9-12 November 2016.
Falanga A.

Trinchero A, Marchetti M, Giaccherini C, Tartari CJ, Russo L, Falanga A.

Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2.


Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party.
Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors.


A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.

Kuderer NM, Culakova E, Lyman GH, Francis C, Falanga A, Khorana AA.


The International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) at the Peak of Adolescence - 15 Years and Counting.

Rickles FR, Brenner B, Falanga A.


Molecular biomarkers of thrombosis in myeloproliferative neoplasms.

Barbui T, Falanga A.


Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study.


The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study.
